Cargando…

Aducanumab: What about the Patient?

Detalles Bibliográficos
Autor principal:	Petersen, Ronald C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Invited Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434994/ https://www.ncbi.nlm.nih.gov/pubmed/34322904 http://dx.doi.org/10.1002/ana.26181

Ejemplares similares

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

How Will Aducanumab Approval Impact AD Research?
por: Weiner, Michael W., et al.
Publicado: (2021)

What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?
por: Wallin, Anders, et al.
Publicado: (2022)

Aducanumab: evidence from clinical trial data and controversies
por: Tampi, Rajesh R, et al.
Publicado: (2021)

Aducanumab for Alzheimer’s disease: The never‐ending story that nurses should know
por: Petch, Joel, et al.
Publicado: (2021)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

Talking about menopause in the workplace
por: Carter, Sarah, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

What We Talk About When We Talk About Training in Endoscopic Sleeve Gastroplasty
por: Hadi, Yousaf, et al.
Publicado: (2023)

What is global health?
por: Beaglehole, Robert, et al.
Publicado: (2010)

Conclusions about testosterone therapy and cardiovascular risk
por: Anawalt, Bradley D, et al.
Publicado: (2018)

Of ethically compromising positions and blatant lies about ‘truth serum’
por: Kala, A. K.
Publicado: (2007)

Topical Insights Into the Post-Approval Controversies of Aducanumab
por: Kumar, Dhiraj, et al.
Publicado: (2021)

Re: Aducanumab-Related ARIA: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

What about microsaccades in the electroencephalogram of infants?
por: Köster, Moritz
Publicado: (2016)

Vaginal mesh: What lessons have we learnt?
por: Robinson, Dudley, et al.
Publicado: (2020)

What is the role of paramedics in palliative and end of life care?
por: Blackmore, Tania Anne
Publicado: (2022)

Should Canadian patients look forward to aducanumab for Alzheimer disease?
por: Watt, Jennifer A., et al.
Publicado: (2021)

Alzheimer disease neuropathology in a patient previously treated with aducanumab
por: Plowey, Edward D., et al.
Publicado: (2022)

Cardiac remodelling and exercise: What happens with ultra-endurance exercise?
por: Dockerill, Cameron, et al.
Publicado: (2020)

Fetal MRI of the supratentorial brain abnormalities: what we should know about ventriculomegaly?
por: Kuwashima, Shigeko
Publicado: (2023)

Estimated Annual Spending on Aducanumab in the US Medicare Program
por: Mafi, John N., et al.
Publicado: (2022)

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
por: Vaz, Miguel, et al.
Publicado: (2022)

What is new in ACC/AHA 2017 focused update of valvular heart disease guidelines
por: Özkan, Mehmet
Publicado: (2017)

Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
por: Herring, William L., et al.
Publicado: (2021)

“Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
por: Padovani, Alessandro, et al.
Publicado: (2021)

What do the “new” Pulmonary Hypertension Guidelines tell us: should we change our practice?
por: Kaymaz, Cihangir, et al.
Publicado: (2016)

What's new in sports cardiology? Hot topics from “Sport and Heart,” First International Congress in Sports Cardiology
por: Fusco, Liuba, et al.
Publicado: (2023)

Canada, global vaccine supply, and the TRIPS waiver: Le Canada, l’offre mondiale de vaccins et l’exemption ADPIC
por: Labonté, Ronald, et al.
Publicado: (2021)

What about It?
Publicado: (1890)

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
por: Lalli, Giovanna, et al.
Publicado: (2021)

Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review
por: Beshir, Semira Abdi, et al.
Publicado: (2022)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Physical Activity and Physical Fitness in Pediatric Obesity: What are the First Steps for Clinicians? Expert Conclusion from the 2016 ECOG Workshop
por: O’MALLEY, GRACE, et al.
Publicado: (2017)

Editorial: gut microbial profile associated with primary sclerosing cholangitis—what is new and how do we progress from here? Authors’ reply
por: Rühlemann, Malte, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ob7nmb4mv3stvk2p2fcirjbj9e